NCT01500629View on ClinicalTrials.gov

Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Rhinitis, Allergic, Seasonal
Interventions
DEVICE

C-1266-7

Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.

DEVICE

C-1266-6 (placebo)

Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.

Trial Locations (1)

60637

The University of Chicago, Chicago

All Listed Sponsors
collaborator

Johnson & Johnson Consumer and Personal Products Worldwide

INDUSTRY

lead

McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.

INDUSTRY

NCT01500629 - Study of a Topical Nasal Spray to Ease the Symptoms of Hayfever | Biotech Hunter | Biotech Hunter